CHA Vaccine Institute Co. Ltd.
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in p… Read more
CHA Vaccine Institute Co. Ltd. (261780) - Total Liabilities
Latest total liabilities as of September 2025: ₩22.26 Billion KRW
Based on the latest financial reports, CHA Vaccine Institute Co. Ltd. (261780) has total liabilities worth ₩22.26 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CHA Vaccine Institute Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how CHA Vaccine Institute Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CHA Vaccine Institute Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of CHA Vaccine Institute Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jaanh CosmeticsInc.
KQ:219550
|
Korea | ₩17.22 Billion |
|
Ray Co. Ltd
KQ:228670
|
Korea | ₩122.77 Billion |
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
India | ₹461.88 Million |
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩33.62 Billion |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
USA | $40.13 Million |
|
Singapore Shipping Corporation Limited
F:W1M
|
Germany | €60.81 Million |
|
Sewoon Medical Co. Ltd
KQ:100700
|
Korea | ₩8.68 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down CHA Vaccine Institute Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CHA Vaccine Institute Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CHA Vaccine Institute Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of CHA Vaccine Institute Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩19.53 Billion | +101.25% |
| 2023-12-31 | ₩9.70 Billion | -64.98% |
| 2022-12-31 | ₩27.70 Billion | +7.80% |
| 2021-12-31 | ₩25.70 Billion | +6.30% |
| 2020-12-31 | ₩24.17 Billion | +31.51% |
| 2019-12-31 | ₩18.38 Billion | -- |